Compare Hilton Hotels Corporation Common Stock (HLT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? Hilton Hotels Corporation Common Stock trades at $326.56 (market cap $72.76B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 7.2× State Street SPDR S&P Biotech ETF's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hilton Hotels Corporation Common Stock for 138 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| HLT | XBI | |
|---|---|---|
Market Cap | $72.76B | $10.11B |
Volume | 1,148,634 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $350.22 | $169.55 |
52-Week Low | $256.96 | $104.99 |
Typical Hold Time | 138 Days | 38 Days |
Enterprise Value | $85.78B | — |
Dividend Yield | 0.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide (HLT) trades at $323.29, up 0.87% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. Revenue grew to $12.04B in 2025, with a net income margin of 12.69%, though valuation ratios like a P/E of 47.47 appear elevated. Recent news highlights institutional buying and the upcoming Q3 2026 earnings report on October 27, 2026.
The outlook is positive with analyst consensus at Buy (57% of 49 analysts) and a $348.11 price target, but risks include high debt levels (debt-to-asset ratio of 73.88% in 2025) and reliance on travel demand. Upside hinges on continued revenue growth and margin stability amid economic uncertainties.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
